Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kenzo Kaneko is active.

Publication


Featured researches published by Kenzo Kaneko.


Internal Medicine | 2016

Fulminant Type 1 Diabetes Mellitus Associated with Coxsackie Virus Type A2 Infection: A Case Report and Literature Review

Nobumasa Ohara; Masanori Kaneko; Takeaki Nishibori; Kazuhiro Sato; Tatsuo Furukawa; Tadashi Koike; Hirohito Sone; Kenzo Kaneko; Kyuzi Kamoi

A 65-year-old Japanese man presented to our hospital in June 2013 with a 6-day history of fever and fatigue, a 24-h history of thirst, and polyuria. His temperature was 37.8°C and he was alert. However, laboratory tests revealed severe hyperglycemia, undetectable C-peptide levels, and diabetic ketoacidosis. Serum antibody testing confirmed a Coxsackie virus A2 infection. A variety of viral infections are reported to be involved in the development of fulminant type 1 diabetes mellitus (FT1D). Our patient is the first reported case of FT1D associated with Coxsackie virus A2 infection and supports the etiological role of common viral infections in FT1D.


Journal of Medical Case Reports | 2016

Vildagliptin-induced acute lung injury: a case report.

Nobumasa Ohara; Masanori Kaneko; Kazuhiro Sato; Ryoko Maruyama; Tomoyasu Furukawa; Junta Tanaka; Kenzo Kaneko; Kyuzi Kamoi

BackgroundDipeptidyl peptidase-4 inhibitors are a class of oral hypoglycemic drugs and are used widely to treat type 2 diabetes mellitus in many countries. Adverse effects include nasopharyngitis, headache, elevated serum pancreatic enzymes, and gastrointestinal symptoms. In addition, a few cases of interstitial pneumonia associated with their use have been reported in the Japanese literature. Here we describe a patient who developed drug-induced acute lung injury shortly after the administration of the dipeptidyl peptidase-4 inhibitor vildagliptin.Case presentationA 38-year-old Japanese woman with diabetes mellitus developed acute respiratory failure 1 day after administration of vildagliptin. Chest computed tomography revealed nonsegmental ground-glass opacities in her lungs. There was no evidence of bacterial pneumonia or any other cause of her respiratory manifestations. After discontinuation of vildagliptin, she recovered fully from her respiratory disorder. She received insulin therapy for her diabetes mellitus, and her subsequent clinical course has been uneventful.ConclusionsThe period of drug exposure in previously reported cases of patients with drug-induced interstitial pneumonia caused by dipeptidyl peptidase-4 inhibitor varied from several days to over 6 months. In the present case, our patient developed interstitial pneumonia only 1 day after the administration of vildagliptin. The precise mechanism of her vildagliptin-induced lung injury remains uncertain, but physicians should consider that dipeptidyl peptidase-4 inhibitor-induced lung injury, although rare, may appear acutely, even within days after administration of this drug.


Internal Medicine | 2016

Rapid Normalization of High Glutamic Acid Decarboxylase Autoantibody Titers and Preserved Endogenous Insulin Secretion in a Patient with Diabetes Mellitus: A Case Report and Literature Review

Nobumasa Ohara; Masanori Kaneko; Tatsuo Furukawa; Tadashi Koike; Hirohito Sone; Shoichiro Tanaka; Kenzo Kaneko; Kyuzi Kamoi

A 59-year-old Japanese woman developed diabetes mellitus without ketoacidosis in the presence of glutamic acid decarboxylase autoantibody (GADA) (24.7 U/mL). After the amelioration of her hyperglycemia, the patient had a relatively preserved serum C-peptide level. Her endogenous insulin secretion capacity remained almost unchanged during 5 years of insulin therapy. The patients GADA titers normalized within 15 months. The islet-related autoantibodies, including GADA, are believed to be produced following the autoimmune destruction of pancreatic beta cells and are predictive markers of type 1 diabetes mellitus. Therefore, the transient appearance of GADA in our patient may have reflected pancreatic autoimmune processes that terminated without progression to insulin deficiency.


Clinical Case Reports | 2018

A case of normotensive incidentally discovered adrenal pheochromocytoma

Nobumasa Ohara; Masanori Kaneko; Yuta Yaguchi; Hajime Ishiguro; Fumio Ishizaki; Ryo Maruyama; Kazuya Suzuki; Takeshi Komeyama; Hiroyuki Usuda; Yuto Yamazaki; Hironobu Sasano; Kenzo Kaneko; Kyuzi Kamoi

Pheochromocytomas are catecholamine‐producing neuroendocrine tumors that arise from the adrenal medulla. The clinical presentation includes headache, palpitation, and hypertension, but pheochromocytomas are sometimes clinically silent. The present case highlights the importance of biochemical testing for pheochromocytoma in patients with adrenal incidentaloma, even if they are completely normotensive and asymptomatic.


Respiratory medicine case reports | 2017

Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1

Nobumasa Ohara; Masanori Kaneko; Masahiro Ikeda; Fumio Ishizaki; Kazuya Suzuki; Ryo Maruyama; Takeshi Komeyama; Kazuhiro Sato; Kenichi Togashi; Hiroyuki Usuda; Yuto Yamazaki; Hironobu Sasano; Kenzo Kaneko; Kyuzi Kamoi

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder caused by heterozygous germline mutations in the tumor suppressor gene MEN1, which encodes a nuclear protein, menin. MEN1 is characterized by the combined occurrence of tumors involving the pituitary gland, pancreatic islets, and parathyroid glands. Additionally, patients with MEN1 often exhibit adrenal tumors. Although most MEN1-associated tumors are benign, malignant lesions arising in these endocrine organs have been reported. Additionally, malignant diseases of non-endocrine organs concomitant with MEN1 have also been reported. Here, we report a rare case of a MEN1 patient who exhibited adrenocortical carcinoma (ACC) and lung adenocarcinoma (LAC). A 53-year-old Japanese woman was diagnosed with genetically proven MEN1 that initially manifested as parathyroid, pancreatic, and adrenal tumors. During the course of the disease, she developed LAC harboring the epidermal growth factor receptor gene mutations and cortisol-secreting ACC. Both tumors were surgically resected. The tumor cells were immunohistochemically negative for menin. Studies have suggested a causative link between MEN1 gene mutations and ACC, and menin expression may decrease in MEN1-related ACCs. In contrast, there are few reports suggesting a specific role of MEN1 gene mutations in LAC. Menin is often inactivated in the LACs of patients without MEN1. Thus, our patients ACC probably occurred as part of MEN1, whereas the latter had no evident etiological association with her LAC. This case demonstrates the need for physicians to consider the potential development of malignant diseases originating from both endocrine and non-endocrine organs in MEN1 patients.


Internal Medicine | 2016

Acute Exacerbation of Idiopathic Pulmonary Fibrosis Following Treatment for Cushing's Syndrome

Nobumasa Ohara; Masanori Kaneko; Kazuhiro Sato; Hiroyuki Usuda; Junta Tanaka; Takashi Maekawa; Hironobu Sasano; Hideki Katakami; Kenzo Kaneko; Kyuzi Kamoi

A 64-year-old Japanese man with mild reticular shadows in both lungs developed a lung tumor causing ectopic Cushings syndrome. He was prescribed an adrenal inhibitor, which controlled his hypercortisolemia. However, he developed acute exacerbation of idiopathic pulmonary fibrosis (IPF) and died within weeks. Previous studies have suggested a dosage reduction of corticosteroids for IPF as a triggering event for acute exacerbation. The present case suggests that IPF coexisting with Cushings syndrome may have been exacerbated after the correction of hypercortisolemia. Therefore, close monitoring of cortisol levels along with the clinical course of IPF is required in similar cases that require the correction of hypercortisolemia.


Clinical Case Reports | 2016

A case of central diabetes insipidus associated with cardiac dysfunction

Nobumasa Ohara; Masanori Kaneko; Tatsuya Suwabe; Tasuku Yoshie; Hiroyuki Kuwano; Katsuya Ebe; Toshio Fujita; Koichi Fuse; Kenzo Kaneko; Kyuzi Kamoi

Central diabetes insipidus (CDI) results from a deficiency of arginine vasopressin (AVP) secretion. It is treated by replacement therapy with the synthetic AVP analogue desmopressin. To prevent heart failure in patients with CDI accompanied by cardiac dysfunction, controlling sodium and water intake is essential, using the minimum effective dose of desmopressin.


Internal Medicine | 2015

Type 1 Diabetes Mellitus and Pernicious Anemia in an Elderly Japanese Patient: A Case Report and Literature Review.

Nobumasa Ohara; Masanori Kaneko; Toshio Yano; Naoko Sato; Hiroyuki Usuda; Masashi Miyakoshi; Tatsuo Furukawa; Tadashi Koike; Kenzo Kaneko; Kyuzi Kamoi

We herein report the case of a 66-year-old Japanese man with acute-onset type 1 diabetes mellitus (T1D) accompanied by pernicious anemia. After 2 weeks of polyuria, the patient developed insulin-deficient hyperglycemia with diabetic ketoacidosis in the absence of verifiable islet-related autoantibodies and began insulin therapy in 2001. Eight years later, he developed gastric autoantibody-positive pernicious anemia and began methylcobalamin treatment. Previous studies have reported cases of slowly progressive autoimmune T1D concomitant with pernicious anemia. The present case suggests that potential associations with organ-specific autoimmune disorders should be considered during the long-term follow-up of T1D patients, even though verifiable islet-related autoantibodies are undetectable.


The Journal of Clinical Endocrinology and Metabolism | 1981

Comparison of the Responses in the Nomifensine Test with Hyperprolactinemia due to Prolactin-Secreting Pituitary Tumors and Nonprolactin-Secreting Hypothalamic Tumors

Kyuzi Kamoi; Isao Tchuchida; Hiroshi Sato; Rhuichi Tanaka; Takao Ishiguro; Kenzo Kaneko; Yoichi Iwasaki; Akira Shibata


Tohoku Journal of Experimental Medicine | 1987

A family case with autosomal-dominantly inherited pituitary dwarfism.

Nagayuki Tani; Kenzo Kaneko; Takeshi Momotsu; Tetsuya Takasawa; Seiki Ito; Akira Shibata; Tetsuro Miki; Hideo Tateishi; Yuichi Kumahara

Collaboration


Dive into the Kenzo Kaneko's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge